Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow, Inc. on February 2, 2026, covering events occurring on January 30, 2026. The Company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol HROW.
Key Financial Metrics and Guidance
The filing does not provide specific revenue, profit, cash flow, or debt figures for the current period. However, it includes a reaffirmation of full-year 2025 revenue guidance.
- 2025 Revenue Guidance: Reaffirmed at between $270 million and $280 million.
- Performance Milestone: Executive compensation is tied to a quarterly revenue target of $230 million.
Material Changes and Executive Appointments
On January 30, 2026, the Company appointed Patrick W. Sullivan as Chief Commercial Officer, effective immediately. Mr. Sullivan previously served as Head of Commercial since August 2025 and brings over 25 years of commercial leadership experience from companies including Corium Therapeutics, AstraZeneca, Shire, and Novartis.
Compensatory Arrangements and Outlook
In connection with his appointment, Mr. Sullivan entered into an Offer Letter with the following terms:
- Base Salary: $425,000 per year.
- Target Annual Bonus: 40% of base compensation, subject to performance targets.
- Restricted Stock Units (RSUs): 40,000 total units awarded.
- 25,000 RSUs vest upon Harrow achieving $230 million in revenue in a calendar quarterly period.
- 15,000 RSUs vest after 3 years from the award date.
The filing states that the information regarding results of operations and financial condition is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the Offer Letter (Exhibit 10.1) for specific performance metrics and vesting conditions.
- Review the press release (Exhibit 99.1) for detailed context on the reaffirmed 2025 revenue guidance.
- Monitor future quarterly reports to assess progress toward the $230 million quarterly revenue milestone tied to executive equity.